Literature DB >> 14606353

[Insulin resistance and diabetes type 2 in overweight children].

C M Renders1, H A Delemarre-van de Waal, J M Dekker, R A Hirasing.   

Abstract

The prevalence of overweight and obesity in children is increasing significantly. This increase is attended by an increase in diabetes type 2 in children and adolescents. The most important risk factor for the rise of insulin resistance amongst young people is overweight. The diagnostic criteria for diabetes mellitus in young people are: (a) symptoms of diabetes mellitus and a random plasma-glucose concentration of > or = 11.1 mmol/l, or (b) fasting plasma-glucose concentration of > or = 7.0 mmol/l, or (c) 2-hour plasma-glucose levels following an oral glucose-tolerance test > or = 11.1 mmol/l. Treatment involves lowering the glucose concentration by changes in lifestyle such as more physical exercise and dieting. In the US, metformin is registered for use in young people. Insulin is indicated in cases of serious hyperglycaemia or diabetic ketoacidosis. Early detection is very useful in obese children with two additional risk factors: diabetes type 2 in first- and second-degree relatives, members of certain ethnic groups or indications of insulin resistance.

Entities:  

Mesh:

Year:  2003        PMID: 14606353

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Prevalence of overweight and obesity in the Netherlands in 2003 compared to 1980 and 1997.

Authors:  Katja van den Hurk; Paula van Dommelen; Stef van Buuren; Paul H Verkerk; Remy A Hirasing
Journal:  Arch Dis Child       Date:  2007-06-29       Impact factor: 3.791

2.  Go4it; study design of a randomised controlled trial and economic evaluation of a multidisciplinary group intervention for obese adolescents for prevention of diabetes mellitus type 2.

Authors:  Geesje H Hofsteenge; Marijke J M Chinapaw; Peter J M Weijs; Maurits W van Tulder; Henriette A Delemarre-van de Waal
Journal:  BMC Public Health       Date:  2008-12-16       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.